<DOC>
	<DOCNO>NCT00024388</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness DHA-paclitaxel treating patient locally advance , metastatic , unresectable kidney cancer .</brief_summary>
	<brief_title>Chemotherapy Treating Patients With Metastatic Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine tumor response rate , duration response , time disease progression patient locally advance , metastatic , unresectable renal cell cancer treat DHA-paclitaxel . II . Determine overall survival patient treated drug . III . Determine toxicity profile drug patient . IV . Assess quality life patient treated drug . OUTLINE : This multicenter study . Patients receive DHA-paclitaxel IV 2 hour day 1 . Treatment repeat every 21 day absence disease progression unacceptable toxicity . Quality life assess baseline , every 2 course , completion treatment . Patients follow every 3 month . PROJECTED ACCRUAL : A total 21-50 patient accrue study .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm renal cell cancer Locally advance OR Metastatic OR Unresectable Measurable disease No known clinical evidence CNS metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT SGPT great 2.5 time ULN Renal : Creatinine great 2.5 mg/dL Cardiovascular : No uncontrolled ventricular arrhythmia No myocardial infarction within past 3 month No superior vena cava syndrome Neurologic : No peripheral neuropathy great grade 1 No uncontrolled major seizure disorder No spinal cord compression Other : No prior malignancy except : Curatively treat nonmelanoma skin cancer carcinoma situ cervix OR Cancer curatively treat surgery alone recur 5 year No concurrent serious infection require parenteral therapy No unstable serious concurrent medical condition No psychiatric disorder would preclude study Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month study PRIOR CONCURRENT THERAPY : Biologic therapy : At least 28 day since prior immunotherapy No concurrent immunotherapy Chemotherapy : No prior chemotherapy advance disease No prior taxanes At least 28 day since prior chemotherapy No concurrent chemotherapy Endocrine therapy : At least 28 day since prior hormonal therapy No concurrent hormonal therapy Radiotherapy : At least 28 day since prior largefield radiotherapy No concurrent radiotherapy Surgery : At least 14 day since prior major surgery Other : Concurrent bisphosphonates allow stable dose least 30 day prior study No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2002</verification_date>
	<keyword>stage III renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
</DOC>